Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loxoprofen + allyl isopropylacetyl urea + anhydrous caffeine
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination drug formulation containing **loxoprofen** (a nonsteroidal anti-inflammatory drug, NSAID), **allyl isopropylacetyl urea** (a sedative-hypnotic, also known as apronalide or apronal), and **anhydrous caffeine** (a central nervous system stimulant)[6]. Loxoprofen acts as a prodrug that is metabolized to an active form, functioning as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), leading to analgesic, anti-inflammatory, and antipyretic effects[6][7][8]. Allyl isopropylacetyl urea is used for its mild sedative and hypnotic actions. Anhydrous caffeine enhances the analgesic effect and provides mild CNS stimulation[6][7].
- Brand names
- Loxonin S Premium
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADOR (Adenosine receptors)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on loxoprofen + allyl isopropylacetyl urea + anhydrous caffeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loxoprofen + allyl isopropylacetyl urea + anhydrous caffeine.